journal
MENU ▼
Read by QxMD icon Read
search

Annals of Oncology: Official Journal of the European Society for Medical Oncology

journal
https://www.readbyqxmd.com/read/30016395/novel-therapies-in-urothelial-carcinoma-a-biomarker-driven-approach
#1
J E Rosenberg, G Iyer
Urothelial malignancies, including carcinomas of the bladder, ureters, and renal pelvis comprised approximately 8% of new cancer cases in the United States in 2016. In the metastatic setting, 15% of patients exhibit long-term survival following cisplatin-based chemotherapy and in patients with recurrent disease, response rates to second-line chemotherapy are generally 15-20% with a 3-month progression-free survival. However, recent advances in immunotherapy represent an opportunity to significantly improve patient outcomes...
July 17, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30016394/ajcc-8th-edition-for-soft-tissue-sarcoma-of-the-extremities-and-trunk
#2
J M M Cates
No abstract text is available yet for this article.
July 17, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30016392/vistusertib-dual-m-torc1-2-inhibitor-in-combination-with-paclitaxel-in-patients-with-high-grade-serous-ovarian-and-squamous-non-small-cell-lung-cancer
#3
B Basu, M G Krebs, R Sundar, R H Wilson, J Spicer, R Jones, M Brada, D C Talbot, N Steele, A H Ingles Garces, W Brugger, E A Harrington, J Evans, E Hall, H Tovey, F M de Oliveira, S Carreira, K Swales, R Ruddle, F I Raynaud, B Purchase, J C Dawes, M Parmar, A J Turner, N Tunariu, S Banerjee, J S de Bono, U Banerji
Background: We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients receiving weekly paclitaxel could improve outcomes in such patients. Patients and Methods: In dose escalation, weekly paclitaxel (80 mg/m2) was given 6/7 weeks in combination with two intermittent schedules of vistusertib (dosing starting on the day of paclitaxel): schedule A, vistusertib dosed bd for 3 consecutive days per week (3/7days) and schedule B, vistusertib dosed bd for 2 consecutive days per week (2/7days)...
July 17, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30016391/final-results-of-a-randomized-phase-iii-trial-of-induction-chemotherapy-followed-by-concurrent-chemoradiotherapy-versus-concurrent-chemoradiotherapy-alone-in-patients-with-stage-iva-and-ivb-nasopharyngeal-carcinoma-taiwan-cooperative-oncology-group-tcog-1303
#4
R L Hong, C F Hsiao, L L Ting, J Y Ko, C W Wang, J T C Chang, P J Lou, H M Wang, M H Tsai, S C Lai, T W Liu
Background: Concurrent chemoradiotherapy (CCRT) is superior to radiotherapy alone for treating locoregionally advanced nasopharyngeal carcinoma (NPC). Whether adding induction chemotherapy (IC) further improves the outcome warrants investigation. Patients and methods: This open-label multicenter phase III trial was conducted at 11 institutions in Taiwan. Patients with stage IVA or IVB NPC were randomized to receive IC followed by CCRT (I-CCRT) or CCRT alone. Patients in the I-CCRT arm received 3 cycles of mitomycin C, epirubicin, cisplatin, and 5-fluorouracil/leucovorin (MEPFL)...
July 17, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30016389/diagnosis-assessment-and-management-of-constipation-in-advanced-cancer-esmo-clinical-practice-guidelines
#5
P J Larkin, N I Cherny, D La Carpia, M Guglielmo, C Ostgathe, F Scotté, C I Ripamonti
No abstract text is available yet for this article.
July 17, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30016386/therapeutic-advantage-of-genetically-engineered-salmonella-typhimurium-carrying-short-hairpin-rna-against-inhibin-alpha-subunit-in-cancer-treatment
#6
W Yoon, Y Yoo, Y S Chae, S-H Kee, B M Kim
Background: In contrast to its well-known endocrine function, the role of inhibin in cancer development and therapeutic response is unclear. Salmonella, particularly less toxic attenuated Salmonella strains, are used to treat cancer in two ways. First, Salmonella accumulate around tumors, penetrate the cell barrier, and replicate inside the tumors. Second, Salmonella can act as a vehicle for delivering anti-cancer agents or pro-apoptotic genes to attack tumors. In this study, we aimed to develop a suitable cancer therapeutic strategy by genetically modifying attenuated Salmonella typhimurium to harbor short hairpin RNA (shRNA) expression plasmids targeting alpha subunit of inhibin (sh-INHA)...
July 17, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30010779/plasma-hpv-cell-free-dna-monitoring-in-advanced-hpv-associated-oropharyngeal-cancer
#7
G J Hanna, J G Supplee, Y Kuang, U Mahmood, C J Lau, R I Haddad, P A Jänne, C P Paweletz
Background: Measuring cell-free (cf)DNA in blood and tissues holds significant potential as a minimally invasive method for disease monitoring in cancer. Cancers arising in the oropharynx and causally linked to human papillomavirus (HPV) represent an ideal model in which to interrogate these methods. Patients and methods: We designed an ultrasensitive and quantitative droplet digital (dd)PCR assay to detect the five dominant high-risk HPV subtypes linked to oropharyngeal cancer (OPC)...
July 13, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30010775/value-of-bone-marrow-biopsy-in-hodgkin-lymphoma-patients-staged-by-fdg-pet-results-from-the-german-hodgkin-study-group-trials-hd16-hd17-and-hd18
#8
C-A Voltin, H Goergen, C Baues, M Fuchs, J Mettler, S Kreissl, J Oertl, B Klaeser, A Moccia, A Drzezga, A Engert, P Borchmann, M Dietlein, C Kobe
Background: Bone marrow (BM) involvement defines advanced-stage Hodgkin lymphoma and thus has impact on the assignment to treatment. Our aim was to evaluate whether the established BM biopsy may be omitted in patients if 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) scanning is performed during staging. Patients and methods: Our analysis set consisted of 832 Hodgkin lymphoma patients from the German Hodgkin Study Group trials HD16, HD17, and HD18 who underwent both PET scanning and BM biopsy before treatment...
July 13, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30010772/addressing-the-quality-of-life-needs-of-older-patients-with-cancer-a-siog-consensus-paper-and-practical-guide
#9
F Scotté, P Bossi, E Carola, T Cudennec, P Dielenseger, F Gomes, S Knox, F Strasser
Around 60% of people living with cancer are aged 65 years or older. Older cancer patients face a unique set of age-associated changes, comorbidities, and circumstances that impact on their quality of life (QoL) in ways that are different to those affecting younger patients. A Task Force of the International Society of Geriatric Oncology (SIOG) recommends and encourages all healthcare professionals involved in cancer care to place greater focus on the QoL of older people living with cancer. This paper summarizes current thinking on the key issues of importance to addressing QoL needs of older cancer patients and makes a series of recommendations, together with practical guidance...
July 13, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30010765/combining-plasma-based-biosources-to-predict-treatment-response-in-nsclc-patients
#10
Jillian Wilhelmina Paulina Bracht, Jordi Berenguer, Niki Karachaliou, Martyna Filipska, Rafael Rosell
No abstract text is available yet for this article.
July 13, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30010763/correlation-of-extent-of-alk-fish-positivity-and-crizotinib-efficacy-in-three-prospective-studies-of-alk-positive-patients-with-non-small-cell-lung-cancer
#11
J-C Soria, S N Ho, M Varella-Garcia, A J Iafrate, B J Solomon, A T Shaw, F Blackhall, T S Mok, Y-L Wu, K Pestova, K D Wilner, A Polli, J Paolini, S Lanzalone, S Green, D R Camidge
Background: In clinical trials of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) treated with crizotinib, evaluation of the relationship between the percentage of ALK-positive cells by fluorescence in situ hybridization (FISH)-particularly near the cutoff defining positive status-and clinical outcomes have been limited by small sample sizes. Patients and methods: Data were pooled from three large prospective trials (one single-arm and two randomized versus chemotherapy) of crizotinib in patients with ALK-positive NSCLC determined by Vysis ALK Break Apart FISH using a cutoff of ≥ 15% ALK-positive cells...
July 13, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30010760/original-article-training-and-validation-of-a-novel-4-mirna-ratio-model-micap-for-prediction-of-post-operative-outcome-in-prostate-cancer-patients
#12
L Schmidt, J Fredsøe, H Kristensen, S H Strand, A Rasmussen, S Høyer, M Borre, P Mouritzen, T Ørntoft, K Dalsgaard Sørensen
Background: New molecular biomarkers for prostate cancer (PC) prognosis are urgently needed. Ratio-based models are attractive, as they require no additional normalization. Here, we train and independently validate a novel 4-miRNA prognostic ratio model for PC. Patients and methods: By genome-wide miRNA expression profiling of PC tissue samples from 123 men who underwent radical prostatectomy (RP) (PCA123, training cohort), we identified six top candidate prognostic miRNAs and systematically tested their ability to predict post-operative biochemical recurrence (BCR)...
July 13, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30010759/the-legacy-of-thomas-tursz-building-a-leading-comprehensive-cancer-center-in-europe
#13
Jean-Charles Soria, Jose Baselga, Martine Piccart
No abstract text is available yet for this article.
July 13, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30010756/adjuvant-bevacizumab-for-melanoma-patients-at-high-risk-of-recurrence-survival-analysis-of-the-avast-m-trial
#14
P G Corrie, A Marshall, P D Nathan, P Lorigan, M Gore, S Tahir, G Faust, C G Kelly, M Marples, S J Danson, E Marshall, S J Houston, R E Board, A M Waterston, J P Nobes, M Harries, S Kumar, A Goodman, A Dalgleish, A Martin-Clavijo, S Westwell, R Casasola, D Chao, A Maraveyas, P M Patel, C H Ottensmeier, D Farrugia, A Humphreys, B Eccles, G Young, E O Barker, C Harman, M Weiss, K A Myers, A Chhabra, S H Rodwell, J A Dunn, M R Middleton
Background: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor (VEGF) shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence. Patients and Methods: Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive either adjuvant bevacizumab (7.5 mg/kg IV 3 weekly for 1 year) or standard observation...
July 13, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30010751/nintedanib-for-the-treatment-of-patients-with-refractory-metastatic-colorectal-cancer-lume-colon-1-a-phase-iii-international-randomized-placebo-controlled-study
#15
E Van Cutsem, T Yoshino, H J Lenz, S Lonardi, A Falcone, M L Limón, M Saunders, A Sobrero, Y S Park, R Ferreiro, Y S Hong, J Tomasek, H Taniguchi, F Ciardiello, J Stoehr, Z Oum'Hamed, S Vlassak, M Studeny, G Argiles
Background: Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. This global, randomized, phase III study investigated the efficacy and safety of nintedanib in patients with refractory CRC after failure of standard therapies. Patients and methods: Eligible patients (Eastern Cooperative Oncology Group performance status 0-1, with histologically/cytologically confirmed metastatic/locally advanced CRC adenocarcinoma unamenable to surgery and/or radiotherapy) were randomized 1:1 to receive nintedanib (200 mg twice daily) or placebo (twice daily), until disease progression or undue toxicity...
July 13, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29992324/reply-to-the-letter-to-the-editor-what-type-of-man-against-machine-by-h-smith
#16
H A Haenssle, C Fink
No abstract text is available yet for this article.
July 10, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29992308/delirium-in-adult-cancer-patients-esmo-clinical-practice-guidelines
#17
S H Bush, P G Lawlor, K Ryan, C Centeno, M Lucchesi, S Kanji, N Siddiqi, A Morandi, D H J Davis, M Laurent, N Schofield, E Barallat, C I Ripamonti
No abstract text is available yet for this article.
July 10, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29992285/reply-to-the-letter-to-the-editor-age-at-diagnosis-and-prognosis-among-prostate-cancer-patients-treated-with-radiotherapy-evidenced-from-three-independent-cohort-studies-by-x-dong-g-ma-and-f-chen
#18
A Pettersson, D Robinson, H Garmo, L Holmberg, P Stattin
No abstract text is available yet for this article.
July 10, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29992258/now-the-dust-has-settled-over-immune-checkpoint-blockade-in-metastatic-prostate-cancer
#19
N Mehra, W Gerritsen
No abstract text is available yet for this article.
July 10, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29992296/age-at-diagnosis-and-prognosis-among-prostate-cancer-patients-treated-with-radiotherapy-evidenced-from-three-independent-cohort-studies
#20
X Dong, G Ma, F Chen
No abstract text is available yet for this article.
July 9, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
journal
journal
30452
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"